Business Context and Reporting Period
Company: Gain Therapeutics, Inc. (GANX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Gain Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapeutics for central nervous system (CNS) disorders, lysosomal storage disorders, and metabolic diseases. The company utilizes its Magellan™ computational platform to identify allosteric binding sites on proteins. Its lead product candidate, rexaceract (formerly GT-02287), is being developed for the treatment of Parkinson's disease.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,284,303) | $(10,339,145) |
| Net Loss Per Share (Basic & Diluted) | $(0.24) | $(0.35) |
| Cash and Cash Equivalents (as of June 30, 2026) | $13,084,144 | $20,837,628 (as of Dec 31, 2025) |
| Cash Used in Operating Activities | $(9,407,532) | $(8,920,509) |
| Total Debt (Current + Noncurrent) | $343,686 | $400,953 (as of Dec 31, 2025) |
| Accumulated Deficit | $(111,640,310) | $(101,356,007) (as of Dec 31, 2025) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $576,295 to $10.0 million for the six months ended June 30, 2026, compared to $9.5 million in the prior year period.
- Research and Development (R&D): Decreased slightly by $114,439 to $4.9 million, driven by lower costs for the lead program and personnel optimization, partially offset by the expiration of the Innosuisse grant in April 2026 and unfavorable foreign exchange rates.
- General and Administrative (G&A): Increased by $690,734 to $5.1 million, primarily due to higher professional fees, personnel costs, and foreign exchange translation impacts.
- Foreign Exchange: The company reported a foreign exchange gain of $49,089 for the three months ended June 30, 2026, a significant improvement from a loss of $620,924 in the same period in 2025. For the six-month period, the loss narrowed to $116,084 from $721,510.
- Liquidity: Cash and cash equivalents decreased by approximately $7.8 million during the six-month period, primarily due to operating cash outflows, partially offset by financing activities.
Guidance, Outlook, and Risks
- Going Concern: The company has disclosed substantial doubt about its ability to continue as a going concern. With $13.1 million in cash as of June 30, 2026, management estimates resources will be sufficient only through the second quarter of 2027. Additional capital is required to fund operations beyond this date.
- Financing Strategy: Management plans to raise capital through public/private equity offerings, debt financing, grants, and strategic collaborations. The company continues to utilize its At-The-Market (ATM) program, raising $1.8 million in net proceeds during the six months ended June 30, 2026.
- Clinical Progress:
- Received FDA authorization in June 2026 to commence a Phase 2 study of rexaceract in Parkinson's disease, anticipated to begin in Q3 2026.
- Phase 1b study enrollment is ongoing, with 16 of 19 participants electing to continue into the extension phase.
- Risks: Key risks include the inability to secure additional financing, failure of clinical trials, regulatory delays, and macroeconomic instability affecting capital markets.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion and the status of any pending financing rounds or grant applications.
- Phase 2 Initiation: Confirm the start date and enrollment progress of the Phase 2 study for rexaceract following FDA authorization.
- ATM Program Utilization: Monitor the remaining capacity and execution pace of the $50 million ATM program.
- Legal Proceedings: Review the status of the lawsuit filed by Andrew Schwartzberg regarding warrant exercise prices, which seeks damages in excess of $3.1 million.
- Grant Expirations: Assess the impact of the expired Innosuisse grant on future R&D budgeting and the timeline for securing replacement funding.